Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity in the provided transcript. CAPEX investments are primarily funded through internal accruals and careful investment decisions. Kuldeep Jain mentioned being open to investing in new CAPEX only if there is a strong business case. No explicit plans or guidance about raising fresh capital through debt or equity were disclosed during the call. The company is focusing on utilizing existing capacities and strategic debottlenecking to enhance growth and returns.

Any current/future capex/capital investment/strategic investment?

FY24 CAPEX was about Rs.230 crores, with approximately Rs.140 crores spent on the animal health segment (page 16). The animal health plant has started operations and no immediate further CAPEX is planned unless future debottlenecking or additional reactors are needed (page 16). For FY25, estimated CAPEX is around Rs.100-120 crores, mainly for debottlenecking and infrastructure upgrades (page 9). Beyond FY25, the company is open to CAPEX investments provided there is a strong business case (page 9). Most CAPEX in recent years focused 55-60% on growth initiatives, with commercial supply starting

Future growth expectations in sales/revenue/volumes?

Hikal targets a medium-term sales growth of 12-15% annually, driven by the pharmaceutical and crop protection segments. The company expects the animal health business to contribute significantly, aiming for commercial-scale production and revenue ramp-up over 2-2.5 years post-validation. Crop protection business anticipates recovery towards the end of FY25, after destocking and inventory normalization. The CDMO business maintains a strong pipeline with consistent new product launches, expected to increase the CDMO share back to historical levels. New multi-purpose facility and CAPEX investment

Future growth expectations in earnings/operating earnings/profits/EPS?

Hikal Limited expects steady top-line growth of 12-15% over the next 3-5 years, driven by pharma and crop protection segments. Pharma business shows a positive trend with stabilized raw material prices and improved margin profile; EBIT margin for Q4 FY24 was 15.9%. EBITDA margin improved by 220 basis points YoY to 18.4% in Q4 FY24, with strong sequential revenue growth of 15%. Full capacity utilization and new growth CAPEX ramp-up over the next 2-3 years is expected to drive margins above 20% and ROCE into the high teens. Animal health segment expected to contribute commercial quantiti

Current/ Expected Orderbook/ Pending Orders?

The CDMO business maintains a healthy pipeline of enquiries from both current and prospective clients. Numerous projects in the crop protection segment are in the advanced stage of discussion with existing innovator customers and new clients, expected to come onstream in the next few years. There is strong interest from global innovators to move supply chains out of China, leading to new project opportunities in India with new chemistries and technologies. The company is focused on molecules with better margin profiles to strengthen its position and drive mid-to-long-term growth. Valid

HikalQ4 FY24Pharmaceuticals & Biotechnology

Hikal Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 63.3Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Hikal targets a medium-term sales growth of 12-15% annually, driven by the pharmaceutical and crop protection segments.
The company expects the animal health business to contribute significantly, aiming for commercial-scale production and revenue ramp-up over 2-2.5 years post-validation.
Crop protection business anticipates recovery towards the end of FY25, after destocking and inventory normalization.
The CDMO business maintains a strong pipeline with consistent new product launches, expected to increase the CDMO share back to historical levels.
New multi-purpose facility and CAPEX investments (about Rs. 200+ crores) are expected to support volume growth and capacity utilization improvements starting FY25-26.
Growth in legacy APIs and food ingredients pipeline (expected peak around 2026) will add to revenue.
Overall, the company is optimistic about the medium to long-term growth potential due to supply chain shifts from China and demand recovery.

Margin guidance

Category 1

Hikal Limited expects steady top-line growth of 12-15% over the next 3-5 years, driven by pharma and crop protection segments.
Pharma business shows a positive trend with stabilized raw material prices and improved margin profile; EBIT margin for Q4 FY24 was 15.9%.
EBITDA margin improved by 220 basis points YoY to 18.4% in Q4 FY24, with strong sequential revenue growth of 15%.
Full capacity utilization and new growth CAPEX ramp-up over the next 2-3 years is expected to drive margins above 20% and ROCE into the high teens.
Animal health segment expected to contribute commercial quantities in 14-18 months post-validation, potentially adding Rs.300-400 crores revenue over 4-5 years.
Crop protection business is poised for medium to long-term recovery post current destocking and price pressures, with normalization expected by end of FY25.
Focus on global innovators and CDMO segment with better margin profiles to strengthen operating profits.

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific mention of new fundraising through debt or equity in the provided transcript.
CAPEX investments are primarily funded through internal accruals and careful investment decisions.
Kuldeep Jain mentioned being open to investing in new CAPEX only if there is a strong business case.
No explicit plans or guidance about raising fresh capital through debt or equity were disclosed during the call.
The company is focusing on utilizing existing capacities and strategic debottlenecking to enhance growth and returns.

Order book

The CDMO business maintains a healthy pipeline of enquiries from both current and prospective clients.
Numerous projects in the crop protection segment are in the advanced stage of discussion with existing innovator customers and new clients, expected to come onstream in the next few years.
There is strong interest from global innovators to move supply chains out of China, leading to new project opportunities in India with new chemistries and technologies.
The company is focused on molecules with better margin profiles to strengthen its position and drive mid-to-long-term growth.
Validation batches for animal health products are ongoing, with commercial orders expected to start about 14 to 18 months post-validation.
Overall, there is a strong orderbook and encouraging enquiries indicating a positive outlook for upcoming contract wins and volume ramp-ups.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes

FY24 CAPEX was about Rs.230 crores, with approximately Rs.140 crores spent on the animal health segment (page 16).
The animal health plant has started operations and no immediate further CAPEX is planned unless future debottlenecking or additional reactors are needed (page 16).
For FY25, estimated CAPEX is around Rs.100-120 crores, mainly for debottlenecking and infrastructure upgrades (page 9).
Beyond FY25, the company is open to CAPEX investments provided there is a strong business case (page 9).
Most CAPEX in recent years focused 55-60% on growth initiatives, with commercial supply starting from H2 FY26 (page 9).
Debottlenecking opportunities with high short-term ROI exist in food ingredients, pharma, and crop protection segments (page 9).
No major new CAPEX is expected next year unless big new contracts or business requirements arise (page 9).

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHikal

Rev 3Mar 1

See where Hikal sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →